Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriella D'Andrea

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Radiology|August 5, 2025
In Vivo Imaging for Assessing Receptor Status in Breast CancerRandy Yeh, Gabriella D'Andrea
Clinical Nuclear Medicine|May 4, 2013
Breast implant foreign body reaction mimicking breast cancer recurrence on FDG PET/CTGary A Ulaner, Gabriella D'Andrea, Hiram S Cody
Clinical Breast Cancer|September 1, 2006
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancerShanu Modi, Gabriella D'Andrea, Larry Norton, et al.
Journal of Cancer Research and Clinical Oncology|March 3, 2009
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effectsGary Deng, Hong Lin, Andrew Seidman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.
Breast Cancer Research and Treatment|September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancerDevika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.
Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.
Clinical Breast Cancer|August 14, 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerAlison K Conlin, Andrew D Seidman, Ariadne Bach, et al.
Journal of the American Geriatrics Society|July 27, 2006
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapyArti Hurria, Anju Hurria, Enid Zuckerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Radiology|August 5, 2025
In Vivo Imaging for Assessing Receptor Status in Breast CancerRandy Yeh, Gabriella D'Andrea
Clinical Nuclear Medicine|May 4, 2013
Breast implant foreign body reaction mimicking breast cancer recurrence on FDG PET/CTGary A Ulaner, Gabriella D'Andrea, Hiram S Cody
Clinical Breast Cancer|September 1, 2006
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancerShanu Modi, Gabriella D'Andrea, Larry Norton, et al.
Journal of Cancer Research and Clinical Oncology|March 3, 2009
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effectsGary Deng, Hong Lin, Andrew Seidman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.
Breast Cancer Research and Treatment|September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancerDevika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.
Breast Cancer Research and Treatment|April 2, 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi, Andrew D Seidman, Maura Dickler, et al.
Clinical Breast Cancer|August 14, 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerAlison K Conlin, Andrew D Seidman, Ariadne Bach, et al.
Journal of the American Geriatrics Society|July 27, 2006
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapyArti Hurria, Anju Hurria, Enid Zuckerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
Pageof 3